Form 8-K - Current report:
SEC Accession No. 0001104659-25-036483
Filing Date
2025-04-21
Accepted
2025-04-21 06:30:17
Documents
15
Period of Report
2025-04-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2512707d4_8k.htm   iXBRL 8-K 48181
2 EXHIBIT 2.1 tm2512707d4_ex2-1.htm EX-2.1 22694
3 EXHIBIT 99.1 tm2512707d4_ex99-1.htm EX-99.1 32445
  Complete submission text file 0001104659-25-036483.txt   299409

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA alms-20250420.xsd EX-101.SCH 3008
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE alms-20250420_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alms-20250420_pre.xml EX-101.PRE 22354
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2512707d4_8k_htm.xml XML 3678
Mailing Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 650-231-6625
ALUMIS INC. (Filer) CIK: 0001847367 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42143 | Film No.: 25851264
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)